By Eleanor McDermid, Senior medwireNews Reporter
The Swedish neonatal screening programme successfully detected all cases of clinically classified salt-wasting congenital adrenal hyperplasia (CAH) during a 26-year period, researchers report.
The findings, which include data on 99.8% of infants born in Sweden between 1986 and 2011, contradict fears that CAH screening misses cases and results in a high recall rate. The recall rate was just 0.03% in full-term infants and 0.57% in preterm infants.
The recall rate was affected by changes made to screening procedures; 17α-hydroxyprogesterone was initially analysed by radioimmunoassay, but later by a dissociation-enhanced, lanthanide fluorescence immunoassay. Thresholds for a positive result were also altered in response the introduction of new antibodies, which affected recall rates.
Of 2,737,932 Swedish infants, 274 had CAH, of whom 231 had a positive screening test, giving a sensitivity of 84.3% for all forms of CAH, with no difference between girls and boys.
The researchers, led by Sebastian Gidlöf (Karolinska Institutet, Stockholm, Sweden), note that this sensitivity is markedly lower than that in previous studies with shorter follow-up periods. This is to be expected, they say, “because the true sensitivity of milder forms of CAH can only be evaluated when enough time has passed to allow diagnosis of late-onset cases.”
However, they stress that the primary aim of the screening programme is to reduce mortality arising from salt loss, and in this respect, it was highly effective, as none of the 43 missed cases experienced salt loss.
All of these missed cases were genetically verified, and three had genotypes usually associated with salt wasting. Two of these cases were boys born in the second year of the screening programme, and both had 17α-hydroxyprogesterone levels that exceeded thresholds used in subsequent years. The other case was a girl who had levels well below the cutoff and was identified at the age of 8 years because of other, milder symptoms.
Two infants with confirmed CAH died, of septicaemia and lactic acidosis. Another 39 infants with above-threshold results died before recall, of causes unknown to the researchers; 19 of these infants were born before 28 weeks’ gestation.
In an editorial accompanying the study in JAMA Pediatrics, Beth Tarini (University of Michigan, Ann Arbor, USA) highlights the importance of time in revealing the benefits of screening, saying the findings challenge the idea that screening for CAH is a “lost cause”, and also demonstrate the potential value of genotyping to reduce false-negative results.
However, she cautions: “While DNA may help identify missed cases, it cannot reliably predict disease severity in CAH. For that, we still need time.”
Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.